Molecular docking results indicated that these sensitive drugs can directly bind to the ITPRIPL1 protein, suggesting that ITPRIPL1 may serve as a potential therapeutic target in glioma. This evidence concerns the gene ITPRIPL1 and central nervous system cancer.